TY - JOUR T1 - Thermal Camera Detection of High Temperature for Mass COVID Screening JF - medRxiv DO - 10.1101/2021.05.05.21256285 SP - 2021.05.05.21256285 AU - Richard S. Maguire AU - Matt Hogg AU - Iain D. Carrie AU - Maria Blaney AU - Antonin Couturier AU - Lucy Longbottom AU - Jack Thomson AU - Aimee Thompson AU - Craig Warren AU - David J. Lowe Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/07/2021.05.05.21256285.abstract N2 - The COVID-19 [SARS-COV-2] pandemic has had a devastating global impact, with both the human and socio economic costs being severe. One result of the COVID-19 pandemic is the emergence of an urgent requirement for effective techniques and technologies for screening individuals showing symptoms of infection in a non-invasive and non-contact way. Systems that exploit thermal imaging technology to screen individuals show promise to satisfy the desired criteria, including offering a non-contact, non-invasive method of temperature measurement. Furthermore, the potential for mass and passive screening makes thermal imaging systems an attractive technology where current ‘standard of care’ methods are not practical.Critically, any fever screening solution must be capable of accurate temperature measurement and subsequent prediction of core temperature. This is essential to ensure a high sensitivity in identifying fever while maintaining a low rate of false positives. This paper discusses the results and analysis of a clinical trial undertaken by Thales UK Ltd and the Queen Elizabeth University Teaching Hospital in Glasgow to assess the accuracy and operation of the High Temperature Detection (HTD) system developed by Thales UK Ltd when used in a clinical setting.Results of this single centre prospective observational cohort study show that the measured laboratory accuracy of the Thales HTD system (RMSE=0.1°C) is comparable to the accuracy when used in a clinical setting (RMSE = 0.15°C) when measuring a calibrated blackbody source at typical skin temperature. For measurement of forehead skin temperature, the system produced results commensurate with close contact measurement methods (R = 0.86, Mean error=0.05°C).. Compared to measured tympanic temperatures, measurement of the forehead skin temperature by the HTD system showed a moderate correlation (R = 0.43),), which is stronger than close contact IR forehead thermometers (R = 0.20,0.35) An improved correlation was observed between the maximum facial temperature measured by the HTD system and measured tympanic temperatures (R = 0.53), which is significantly stronger than the close contact methods. A linear predictive model for tympanic temperature based on the measured maximum facial temperatures resulted in a root mean square error (RMSE = 0.50°C) that is marginally larger than what is expected as a compound of errors in the measuring devices (RMSE=0.45°C).The study demonstrates that the HTD could be applied in the clinical and non-clinical setting as a screening mechanism to detect citizens with raised temperature. This approach would enable high volume surveillance and identification of individuals that contribute to further spread of COVID-19. Deployment of the HTD system could be implemented as part of a screening tool to support measures to enhance public safety and confidence in areas of high throughput, such as airports, shopping centres or places of work.Competing Interest StatementThales UK Ltd the designers of HTD camera used in study. The institution of several authors Thales UK Ltd funded the study in partnership with Thales Digital Identity and Security (another Thales Subsidiary) who are working with Thales UK Ltd to deploy the HTD system in numerous applications. Novel and inventive aspects of the HTD system are currently under application for [UK Patent Application No 2011944.2]Clinical TrialNCT04792450Funding StatementThales UK Ltd the designers of HTD camera used in study. The institution of several authors Thales UK Ltd funded the study in partnership with Thales Digital Identity and Security (another Thales Subsidiary) who are working with Thales UK Ltd to deploy the HTD system in numerous applications.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by Camden & Kings Cross Research and Ethics Committee (20/HRA/4413).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo external data was used in the preparation of the manuscript. All trials measurements and data is held by Thales in accordance with the requirements of the Trial and GDPR. All patient consent forms are held and archived by the Queen Elizabeth University Hospital in accordance with the requirements of the trial and GDPR. ER -